Quest Diagnostics Inc (DGX)
61.92USD
23 May 2013
$0.80 (+1.31%)
$61.12
$60.70
$62.04
$60.69
780,169
1,376,549
$64.87
$53.25
DGX
About
Overall
| Beta: | 0.62 |
| Market Cap (Mil.): | $9,658.76 |
| Shares Outstanding (Mil.): | 158.03 |
| Dividend: | 0.30 |
| Yield (%): | 1.96 |
Financials
| DGX | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 16.66 | 28.38 | 35.42 |
| EPS (TTM): | 3.67 | -- | -- |
| ROI: | 7.82 | 6.80 | 18.86 |
| ROE: | 14.55 | 8.33 | 19.73 |
Quest profit misses estimates, deals to drive growth
- Laboratory tests provider Quest Diagnostics Inc, whose earnings have been hurt by Medicare reimbursement cuts, said growth this year will be driven by acquisitions.
Quest profit misses estimates, deals to drive growth
- Laboratory tests provider Quest Diagnostics Inc, whose earnings have been hurt by Medicare reimbursement cuts, said growth this year will be driven by acquisitions.
UPDATE 2-Quest profit misses estimates, deals to drive growth
April 17 - Laboratory tests provider Quest Diagnostics Inc, whose earnings have been hurt by Medicare reimbursement cuts, said growth this year will be driven by acquisitions.
Quest first quarter profit misses estimates
- Laboratory tests provider Quest Diagnostics Inc's quarterly profit missed analysts estimates as Medicare reimbursement cuts ate into its margins, sending its shares down 4 percent before the bell.
Quest 1st-qtr profit misses estimates
April 17 - Laboratory tests provider Quest Diagnostics Inc's first-quarter profit missed Wall Street's average estimate as Medicare reimbursement cuts ate into its revenue.
UPDATE 2-Quest CFO to leave as company restructures
March 14 - Laboratory tests provider Quest Diagnostics on Thursday said its Chief Financial Officer Robert Hagemann will leave at the end of May as the company continues a restructuring aimed at returning to revenue growth.
Quest CFO to step down at the end of May
March 14 - Laboratory tests provider Quest Diagnostics said Chief Financial Officer Robert Hagemann will leave the company at the end of May.
TEXT-Fitch affirms Quest Diagnostics IDR, outlook revised to stable
Feb 22 - Fitch Ratings has affirmed Quest Diagnostics, Inc.'s (Quest) Issuer Default Rating (IDR) at 'BBB+'. A complete list of ratings is provided at the end of this release. The ratings apply to approximately $3.36 billion of outstanding debt. The Rating Outlook is revised to Stable from Negative. KEY RATING DRIVERS Debt Leverage Within Goal Quest has reduced leverage (total debt to EBITDA) during 2012 into its stated target range of 2.0 times (x) to 2.25x, a level Fitch considers to be c
Quest Diagnostics expects reimbursement cuts to hurt in 2013
- Laboratory tests provider Quest Diagnostics Inc's fourth-quarter profit missed analysts' recently cut estimates, and the company forecast 2013 results below market expectations, citing pricing and reimbursement pressures.
UPDATE 3-Quest Diagnostics expects reimbursement cuts to hurt in 2013
Jan 23 - Laboratory tests provider Quest Diagnostics Inc's fourth-quarter profit missed analysts' recently cut estimates, and the company forecast 2013 results below market expectations, citing pricing and reimbursement pressures.
Competitors
| Price | Change | |
|---|---|---|
| Laboratory Corp. of America Holdings (LH.N) | $100.85 | +1.05 |
| Bio-Reference Laboratories Inc (BRLI.OQ) | $31.06 | -0.01 |
| Sonic Healthcare Limited (SHL.AX) | $14.31 | -0.14 |
| Medco Health Solutions Inc. (MHS.N) | -- | -- |
| Ventas, Inc. (VTR.N) | $78.12 | -2.59 |
| Johnson & Johnson (JNJ.N) | $87.53 | -0.27 |
| GlaxoSmithKline plc (GSK.L) | 1,742.00p | -31.00 |
| Pfizer Inc. (PFE.N) | $29.13 | -0.17 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Trading Report for (DGX). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Wright Reports
|
$495.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
